My Cart

TFPI

TFPI Overview

English NameTissue factor pathway inhibitorApproved Drugs2
Drugs in Clinical Trials3Target SynonymTFPI,Tissue Factor Pathway Inhibitor,Extrinsic Pathway Inhibitor,TFPI1,LACI,EPI,Anti-Convertin,TFI,Lipoprotein-associated coagulation inhibitor,Tissue Factor Pathway Inhibitor (Lipoprotein-Associated Coagulation Inhibitor)
Highest Development StageApproved
English NameTissue factor pathway inhibitor
Target SynonymTFPI,Tissue Factor Pathway Inhibitor,Extrinsic Pathway Inhibitor,TFPI1,LACI,EPI,Anti-Convertin,TFI,Lipoprotein-associated coagulation inhibitor,Tissue Factor Pathway Inhibitor (Lipoprotein-Associated Coagulation Inhibitor)
Approved Drugs2
Drugs in Clinical Trials3
Highest Development StageApproved

TFPI Product List

  • Product Category

    Protein (1)

  • Product Status

    Launched (1)

  • Species

    Human (1)

  • Tag

    His Tag (1)

  • Conjugate

    Unconjugated (1)

Cat. No.SpeciesHostProduct DescriptionStructurePurityFeatureOrder Now
TFI-H5226
Human
HEK293
Human TFPI Protein, His Tag (active enzyme)
Add to Cart
Total: 1
  • 1

TFPI Background

Tissue factor pathway inhibitor (TFPI) is also known as Extrinsic pathway inhibitor (EPI), Lipoprotein - associated coagulation inhibitor (LACI), is a plasma proteinase inhibitor synthesized by vascular endothelial cells and part of it is associated with glycosaminoglycans of these cells. TFPI is a single-chain polypeptide which can reversibly inhibit Factor Xa (Xa) and Thrombin (Factor IIa). TFPI is a secreted protein with a N­terminal acidic region, three Kunitz (K) domains separated with by two linker regions, and a C­terminal basic region. The first K domain inhibits coagulation factor VIIa complexed to tissue factor (TF); The second K domain inhibits factor Xa; The third K domain binds to heparin; The C­terminal basic region may have several functions. For example, it plays an important role in binding of TFPI to cell surfaces.

TFPI Synonyms

TFPI,LACI,TFPI1,EPI,TFI

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
KN-057KN-057; KN057Phase 3 ClinicalSuzhou Alphamab Co LtdHemophilia A; Hemophilia B
Details
MG-1113MG-1113; MG-1113APhase 1 ClinicalGC Biopharma CorpHemophilia A
Details
AP-017AP017; AP-017Phase 1 ClinicalAnyuan Pharmaceutical Technology (Shanghai) Co LtdHemophilia A; Hemophilia B
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
ConcizumabAnti-TFPI; mAb-2021; NNC-0172-2021; NNC-172-2021; mAbTFPI2021; NN-7415; NNC-0172-0000-2021ApprovedNovo Nordisk A/SAlhemoCanadaHemophilia BNovo Nordisk Canada Inc2023-04-17Hemophilia A; Hemophilia B; Hemorrhage
Details
MarstacimabPF-6741086; PF-06741086ApprovedPfizer IncHYMPAVZI, 友瑞宁United StatesHemophilia A; Hemophilia BPfizer Inc2024-10-11Hemophilia A; Hemophilia B; Hemorrhage
Details
  • Overview
  • Product List
  • Marketed Drug Information
  • Clinical Drug Information